Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. This expansion broadens access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
According to the company, Epi+Gen CHD evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks.
For industry leaders, this development signals a growing trend toward integrating AI-driven diagnostics into managed care settings. The coverage by Atlas Healthcare Physicians underscores the potential for precision medicine to reduce healthcare costs by enabling early detection and personalized treatment, potentially lowering the burden of cardiovascular disease—a leading cause of death globally. For readers, this means improved access to advanced testing that could lead to more accurate risk assessment and tailored interventions, shifting from reactive to proactive care.
The announcement highlights the practical implications of AI in healthcare: moving beyond theoretical promise to tangible patient impact. By making these tests available through a physician association serving a large managed care population, Cardio Diagnostics is demonstrating how precision diagnostics can be scaled within existing healthcare networks. This could encourage other insurers and provider groups to adopt similar technologies, accelerating the shift toward personalized medicine.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease.
For more information, the full press release is available at https://nnw.fm/EFQen. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially. Forward-looking statements are subject to risks including those set forth under "Risk Factors" in the Company's filings with the SEC. Undue reliance should not be placed on these statements, and all parties undertake no duty to update this information unless required by law.
